Total Payments
$4,017
2024 Payments
$253.44
Companies
4
Transactions
13
Medicare Patients
475
Medicare Billing
$74,103
Payment Breakdown by Category
Consulting$2,674 (66.6%)
Research$1,311 (32.6%)
Food & Beverage$20.94 (0.5%)
Education$11.56 (0.3%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $2,674 | 2 | 66.6% |
| Unspecified | $1,311 | 9 | 32.6% |
| Food and Beverage | $20.94 | 1 | 0.5% |
| Education | $11.56 | 1 | 0.3% |
Payments by Type
General
$2,707
4 transactions
Research
$1,311
9 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $2,674 | 2 | $0 (2024) |
| SANOFI US SERVICES INC. | $1,311 | 9 | $0 (2019) |
| GENZYME CORPORATION | $20.94 | 1 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $11.56 | 1 | $0 (2020) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $253.44 | 2 | Merck Sharp & Dohme LLC ($232.50) |
| 2023 | $2,442 | 1 | Merck Sharp & Dohme LLC ($2,442) |
| 2020 | $11.56 | 1 | AstraZeneca Pharmaceuticals LP ($11.56) |
| 2019 | $1,311 | 9 | SANOFI US SERVICES INC. ($1,311) |
All Payment Transactions
13 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 02/29/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $20.94 | General |
| Category: Immunology | ||||||
| 01/03/2024 | Merck Sharp & Dohme LLC | — | Consulting Fee | Cash or cash equivalent | $232.50 | General |
| Category: RESPIRATORY | ||||||
| 12/18/2023 | Merck Sharp & Dohme LLC | — | Consulting Fee | Cash or cash equivalent | $2,441.50 | General |
| Category: RESPIRATORY | ||||||
| 10/22/2020 | AstraZeneca Pharmaceuticals LP | BREZTRI AEROSPHERE (Drug) | Education | In-kind items and services | $11.56 | General |
| Category: Respiratory | ||||||
| 06/20/2019 | SANOFI US SERVICES INC. | DUPIXENT (Drug) | — | In-kind items and services | $49.23 | Research |
| Study: A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate-to-severe Chronic Obstructi • Category: IMMUNOLOGY | ||||||
| 06/20/2019 | SANOFI US SERVICES INC. | DUPIXENT (Drug) | — | In-kind items and services | $45.01 | Research |
| Study: A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate-to-severe Chronic Obstructi • Category: IMMUNOLOGY | ||||||
| 06/20/2019 | SANOFI US SERVICES INC. | DUPIXENT (Drug) | — | In-kind items and services | $28.95 | Research |
| Study: A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate-to-severe Chronic Obstructi • Category: IMMUNOLOGY | ||||||
| 06/19/2019 | SANOFI US SERVICES INC. | DUPIXENT (Drug) | — | In-kind items and services | $99.50 | Research |
| Study: A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate-to-severe Chronic Obstructi • Category: IMMUNOLOGY | ||||||
| 06/19/2019 | SANOFI US SERVICES INC. | DUPIXENT (Drug) | — | In-kind items and services | $43.83 | Research |
| Study: A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate-to-severe Chronic Obstructi • Category: IMMUNOLOGY | ||||||
| 06/19/2019 | SANOFI US SERVICES INC. | DUPIXENT (Drug) | — | In-kind items and services | $37.38 | Research |
| Study: A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate-to-severe Chronic Obstructi • Category: IMMUNOLOGY | ||||||
| 06/18/2019 | SANOFI US SERVICES INC. | DUPIXENT (Drug) | — | In-kind items and services | $536.64 | Research |
| Study: A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate-to-severe Chronic Obstructi • Category: IMMUNOLOGY | ||||||
| 06/18/2019 | SANOFI US SERVICES INC. | DUPIXENT (Drug) | — | In-kind items and services | $256.68 | Research |
| Study: A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate-to-severe Chronic Obstructi • Category: IMMUNOLOGY | ||||||
| 06/18/2019 | SANOFI US SERVICES INC. | DUPIXENT (Drug) | — | In-kind items and services | $213.57 | Research |
| Study: A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate-to-severe Chronic Obstructi • Category: IMMUNOLOGY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate-to-severe Chronic Obstructi | SANOFI US SERVICES INC. | $1,311 | 9 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 5 | 132 | 185 | $79,816 | $18,995 |
| 2022 | 5 | 120 | 253 | $129,331 | $28,318 |
| 2021 | 4 | 97 | 121 | $28,469 | $10,225 |
| 2020 | 5 | 126 | 189 | $80,814 | $16,565 |
Total Patients
475
Total Services
748
Medicare Billing
$74,103
Procedure Codes
19
All Medicare Procedures & Services
19 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99291 | Critical care, first 30-74 minutes | Facility | 2023 | 21 | 54 | $46,602 | $7,617 | 16.3% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 42 | 48 | $16,512 | $6,009 | 36.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 44 | 48 | $12,240 | $3,841 | 31.4% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 14 | 24 | $4,176 | $1,443 | 34.6% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 11 | 11 | $286.00 | $85.25 | 29.8% |
| 99291 | Critical care, first 30-74 minutes | Facility | 2022 | 20 | 92 | $79,396 | $15,506 | 19.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 62 | 101 | $25,755 | $8,646 | 33.6% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 13 | 34 | $19,500 | $2,751 | 14.1% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 11 | 11 | $4,290 | $1,372 | 32.0% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2022 | 14 | 15 | $390.00 | $42.83 | 11.0% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 59 | 83 | $21,165 | $7,626 | 36.0% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 15 | 15 | $5,850 | $1,691 | 28.9% |
| 90662 | Vaccine for influenza for injection into muscle, split virus, preservation free | Office | 2021 | 11 | 11 | $770.00 | $713.58 | 92.7% |
| G0008 | Administration of influenza virus vaccine | Office | 2021 | 12 | 12 | $684.00 | $194.82 | 28.5% |
| 99291 | Critical care delivery critically ill or injured patient, first 30-74 minutes | Facility | 2020 | 22 | 59 | $50,917 | $8,508 | 16.7% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 55 | 79 | $20,145 | $5,678 | 28.2% |
| 99204 | New patient office or other outpatient visit, typically 45 minutes | Office | 2020 | 17 | 17 | $6,678 | $1,671 | 25.0% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 13 | 15 | $2,580 | $654.35 | 25.4% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2020 | 19 | 19 | $494.00 | $53.58 | 10.8% |
About Dr. Loretta Que, MD
Dr. Loretta Que, MD is a Pulmonary Disease healthcare provider based in Durham, North Carolina. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/25/2006. The National Provider Identifier (NPI) number assigned to this provider is 1245314137.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Loretta Que, MD has received a total of $4,017 in payments from pharmaceutical and medical device companies, with $253.44 received in 2024. These payments were reported across 13 transactions from 4 companies. The most common payment nature is "Consulting Fee" ($2,674).
As a Medicare-enrolled provider, Que has provided services to 475 Medicare beneficiaries, totaling 748 services with total Medicare billing of $74,103. Data is available for 4 years (2020–2023), covering 19 distinct procedure/service records.
Ad
Practice Information
- Specialty Pulmonary Disease
- Location Durham, NC
- Active Since 10/25/2006
- Last Updated 06/02/2008
- Taxonomy Code 207RP1001X
- Entity Type Individual
- NPI Number 1245314137
Products in Payments
- DUPIXENT (Drug) $1,311
- DUPIXENT (Biological) $20.94
- BREZTRI AEROSPHERE (Drug) $11.56
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Pulmonary Disease Doctors in Durham
Laurie Snyder, Md, MD
Pulmonary Disease — Payments: $140,144
Pulmonary Disease $140,144
Scott Palmer, M.d, M.D
Pulmonary Disease — Payments: $125,081
Pulmonary Disease $125,081
Eric Meltzer, Md, MD
Pulmonary Disease — Payments: $42,908
Pulmonary Disease $42,908
Donald Rabil, Md, MD
Pulmonary Disease — Payments: $17,077
Pulmonary Disease $17,077
Thomas Murphy
Pulmonary Disease — Payments: $13,265
Pulmonary Disease $13,265
Dr. Scott Shofer, M.d., Ph.d, M.D., PH.D
Pulmonary Disease — Payments: $8,376
Pulmonary Disease $8,376